We report a patient presenting with acute myeloid leukemia (AML)-M4 Eo, in whom conventional cytogenetic analysis revealed a 46, XY, del(16)(q22) karyotype. Molecular analysis of the bone marrow cells using reverse transcriptase polymerase chain reaction (RT-PCR) identified a CBF-MYH11, "type A" fusion transcript. However, despite a thorough reevaluation, a balanced chromosome 16 abnormality could not be definitively identified by cytogenetics. Since there exists a small possibility of obtaining a false-positive PCR result, fluorescence in situ hybridization (FISH) analysis using dual-color, break-apart probes for CBF was performed to elucidate the mechanism of fusion gene formation and thus confirm the RT-PCR results. FISH analysis clearly revealed a cryptic t(16;16), which was probably masked by the del (16) 1 Rearrangements of the CBF gene define one such prognostically distinct group, which is uniquely associated with, but not restricted to, acute myelomonocytic leukemia with abnormal eosinophils (AML-M4 Eo).2 Rearrangement of the CBF gene results in a fusion gene CBF-MYH11 produced by the juxtaposition of bands 16q22 (containing CBF) and 16p13 (containing MYH11). At the cytogenetic level, this juxtaposition is brought about most commonly by inv(16)(p13;q22) and less commonly by t(16; 16)(p13;q22).
2Patients with CBF-MYH11 AML constitute approximately 10% of all de novo acute myeloid leukemias and have significantly better prognosis as compared with patients with complex chromosomal aberrations or normal karyotype.3 This is especially true for patients who receive intensive post-remission treatment with highdose cytarabine. 4 Consequently, in several treatment protocols, the consolidation therapy of adults with AML has been adapted in a risk-adjusted fashion.5 Patients with CBF-MYH11 AML may achieve continuous complete remission with chemotherapy, rather than proceeding to autologous or allogenic peripheral stem cell transplantation.5 Therefore, detection of these cytogenetic aberrations is of utmost importance in the risk-adjusted stratification of these AML patients.Standard karyotypic analysis remains the "gold-standard" for the detection of cytogenetic aberrations. However, both inv(16) and t(16;16) may be subtle, cryptic, or masked by deletions and thus difficult to detect using standard cytogenetic techniques, especially in metaphase spreads showing suboptimal chromosomal morphology. The mRNA transcripts resulting from CBF-MYH11 gene rearrangement are amenable to detection by reverse transcriptase polymerase chain reaction (RT-PCR); however, there exists a small possibility of falsepositive RT-PCR results, which could theoretically arise